Similar articles

• Does antiretroviral-induced hyperlipidaemia constitute a cardiovascular risk?

  Gilleece Y, Nelson M. Gilleece Y, et al. J HIV Ther. 2001 May;6(2):37-9. J HIV Ther. 2001. PMID: 11501202 Review. No abstract available.
• Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.

  Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group. Friis-Møller N, et al. AIDS. 2003 May 23;17(8):1179-93. doi: 10.1097/01.aids.0000060358.78202.c1. AIDS. 2003. PMID: 12819520
• Effects of sex and race on lipodystrophy pathogenesis.

  Nolan D, Mallal S. Nolan D, et al. J HIV Ther. 2001 May;6(2):32-6. J HIV Ther. 2001. PMID: 11501201 Review. No abstract available.
• Substitution for protease inhibitors in HIV therapy.

  Mikhail E. Mikhail E. N Engl J Med. 2003 Dec 18;349(25):2460-1; author reply 2460-1. N Engl J Med. 2003. PMID: 14689602 No abstract available.
• On the trail of fugitive fat: the chase turns to NRTIs.

  Mascolini M. Mascolini M. J Int Assoc Physicians AIDS Care. 1999 Oct;5(10):24-43. J Int Assoc Physicians AIDS Care. 1999. PMID: 11366871